Home > Patrick Vermersch, MSVirtual2020 – Masitinib in the Treatment of Progressive Multiple Sclerosis (Part 1)
Multiple Sclerosis

Patrick Vermersch, MSVirtual2020 – Masitinib in the Treatment of Progressive Multiple Sclerosis (Part 1)

Published Online: September 22nd 2020

Patrick Vermersch (University of Lille and CHU Lille, Lille, France) shares promising findings and expert insight from the phase 3 study of masitinib for the treatment of progressive multiple sclerosis (ClinicalTrials.gov identifier: NCT01433497). This discussion was based on his MSVirtual2020 presentation: FC04.01 Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002.

Questions
1. What are unmet needs in the treatment of primary progressive multiple sclerosis (MS) and non-active secondary progressive MS? (0:06)
2. Could you tell us a little about masitinb and its mechanism of action? (2:07)

See also the 2nd part of this interview here.

Disclosures: Dr Vermersch reports receiving honoraria and consulting fees from Biogen, Celgene, Novartis, Sanofi-Genzyme, Merck, Roche and Teva; he also receives research support from Novartis, Roche and Sanofi-Genzyme.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.

Share this Video
Related Videos In Multiple Sclerosis
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar